|
US2019167790A1
|
|
Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers
|
|
EP3504242A1
|
|
Anti-ox40 antibodies and their uses
|
|
BR112019004998A2
|
|
anti-pd-1 antibodies (cd279)
|
|
WO2018027195A1
|
|
Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
|
|
SG10201914132RA
|
|
Anti-cd40 antibodies and their uses
|
|
CN109476747A
|
|
In conjunction with the bispecific binding protein of immune regulative albumen and tumour antigen
|
|
EP3464362A1
|
|
Anti-4-1bb antibodies and their uses
|
|
EP3626273A1
|
|
Anti-cmet antibody drug conjugates and methods for their use
|
|
CA2966005A1
|
|
Anti-cs1 antibodies and antibody drug conjugates
|
|
AU2015213401A1
|
|
Therapeutic use of anti-CS1 antibodies
|
|
WO2015035044A2
|
|
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
|
EP3013856A2
|
|
Fc variants with improved complement activation
|
|
US2015010539A1
|
|
Anti-cd25 antibodies and their uses
|
|
EP2970436A2
|
|
Fc variants
|
|
US2015051081A1
|
|
Method of screening complex protein libraries to identify altered properties
|
|
US2014154255A1
|
|
Anti-vegf antibodies and their uses
|
|
MX2015004027A
|
|
Compostions and methods for producing glycoproteins.
|
|
MX2015003541A
|
|
Methods for identifying antibodies with reduced immunogenicity.
|
|
WO2013177386A1
|
|
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
|
WO2013166290A1
|
|
P21 biomarker assay
|
